Definium Therapeutics, Inc. Announces First Patient Dosed In Ascend, The Second Phase 3 Pivotal Study Of DT120 ODT In Major Depressive Disorder
Definium Therapeutics Inc DFTX
$20.99
▼ -1.69%
($-0.36)
Open
$21.05
Prev Close
$21.35
Day Range
$20.80 – $21.42
52W Range
$6.28 – $26.25
Market Cap
$2.29B
Beta
2.41
EPS (TTM)
$-2.49
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2015-05-04 |
| Shares Out. | 99,700,000 |
| Website | definiumtx.com/ ↗ |
| Phone | 12122206633 |
Definium Therapeutics Inc is a publicly traded company under the ticker symbol DFTX on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
22 analysts (2026-05-01)
📰 Latest News for DFTX
Definium Therapeutics Dosed First Patient In Ascend Phase 3 Study Of DT120 ODT (Lysergide Tartrate) For Major Depressive Disorder, Topline Data From The 12-week Double-blind Period Is Anticipated In 2027
Definium Therapeutics announces first patient dosed in Ascend
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Definium Therapeutics Announces New Employee Inducement Grants
Definium Therapeutics, Inc. (DFTX) Q1 2026 Earnings Call Transcript
Transcript : Definium Therapeutics, Inc., Q1 2026 Earnings Call, May 07, 2026
'Health Officials Close To U.S. Secretary Kennedy Explored Ban Of Some Widely Used Antidepressants' - Reuters Exclusive